GlassScriptPhysician profile
Alex Glazer
NPI 1215324447
$267,916.09
in general payments reported to CMS, 2019-2025
36 companies · $178K in 2025
The $178K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.44 · 2020: $1,041 · 2021: $4,937 · 2022: $5,027 · 2023: $27K · 2024: $51K · 2025: $178K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $143K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Travel and Lodging: $13K · Food and Beverage: $12K · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $142,705.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,312.82 |
| Travel and Lodging | $12,745.86 |
| Food and Beverage | $12,076.24 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $138,583.32 | 2023-2025 | Zoryve |
| Ucb, INC. | $73,328.89 | 2021-2025 | Bimzelx, Cimzia |
| Kowa Pharmaceuticals America, INC. | $23,106.32 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $7,934.76 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Abbvie INC. | $5,825.00 | 2020-2025 | |
| Incyte Corporation | $4,825.64 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $2,684.73 | 2022-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,494.65 | 2021-2023 | Cyltezo |
| Epi Health, LLC | $1,610.35 | 2020-2022 | |
| Genzyme Corporation | $966.54 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $900.58 | 2020-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $883.12 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $725.32 | 2020-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $496.32 | 2020-2025 | |
| Leo Pharma INC. | $466.11 | 2020-2025 | Adbry, Anzupgo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $421.39 | 2020-2025 | Nemluvio, Aklief |
| Pfizer INC. | $388.69 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $352.30 | 2019-2025 | |
| Amgen INC. | $322.70 | 2020-2025 | Otezla, Otezla |
| Journey Medical Corporation | $308.21 | 2022-2024 | |
| Dermavant Sciences, INC. | $287.39 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $137.73 | 2020-2024 | Siliq |
| Vyne Pharmaceuticals INC. | $129.44 | 2020-2021 | |
| Allergan, INC. | $123.90 | 2021-2022 | |
| Genentech USA, INC. | $102.44 | 2021-2024 | Erivedge, Xolair |
| Botanix Sb INC | $100.73 | 2025 | Sofdra |
| Smith+Nephew, INC. | $95.77 | 2024-2025 | Grafix Pl |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Verrica Pharmaceuticals INC. | $53.42 | 2024 | Ycanth |
| Celgene Corporation | $52.89 | 2020 | |
| Organon LLC | $26.79 | 2025 | Vtama |
| Kyowa Kirin, INC. | $25.87 | 2025 | |
| Sandoz INC. | $24.23 | 2023 | |
| Almirall LLC | $20.61 | 2023 | Seysara |
| Cipher Pharmaceuticals US LLC | $18.49 | 2025 | Spinosad, Natroba |
| Mission Pharmacal Company | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Glazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.